For this, we employed huCRPtg mice under conditions of HFD-induced obesity in conjunction with two pharmacological interventions, rosiglitazone and rosuvastatin, with established anti-inflammatory properties15, as exemplified by decreased huCRP levels. This evidence concerns the gene ISG15 and obesity disorder.